Recombinant murine interleukin 4 protein therapy for psoriasis in a transgenic VEGF mouse model

Dermatology

Volumn 219, Issue 3, 2009, Pages 232-238

  Ren, Xiaoxiao ^a   Li, Jiong ^a   Zhou, Xikun ^a   Luo, Xiaolei ^a   Huang, Nongyu ^a   Wang, Yongsheng ^a   Chen, Xiancheng ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Murine interleukin 4 protein; Psoriasis; Transgenic mouse model; Vascular endothelial growth factor

Indexed keywords

CD31 ANTIGEN; EOSIN; GAMMA INTERFERON; HEMATOXYLIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; MESSENGER RNA; RECOMBINANT INTERLEUKIN 4; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; EPIDERMIS; ERYTHEMA; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; SKINFOLD THICKNESS; STAINING; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TISSUE SECTION; TRANSGENIC MOUSE; TREATMENT RESPONSE;

ANIMALS; DISEASE MODELS, ANIMAL; EAR; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INJECTIONS; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PSORIASIS; RECOMBINANT PROTEINS; RNA, MESSENGER; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350324675     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000235974     Document Type: Article

References (25)

1. Lowe NJ: Psoriasis: in vivo models for topical drug evaluation. Drug Dev Res 1988; 13: 147-155.
2. Ziboh VA: Psoriasis: hyperproliferative/inflammatory skin disorder. Drug Dev Res 1988; 13: 137-146.
3. Nickoloff BJ, Nestle FO: Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-1675.
4. Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-1110.
5. Lowes MA, Bowcock AM, Krueger JG: Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-873.
6. Ghoreschi K, Thomas P, Breit S, Dugas M, et al: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9: 40-46.
7. Röcken M, Racke M, Shevach EM: Il-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol Today 1996; 17: 225-231.
8. Villadsen LS, Schuurman J, Beurskens F, Dam TN, et al: Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003; 112: 1571-1580.
9. Duan H, Koga T, Kohda F, Hara H, et al: Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 2001; 26: 119-124.
10. Gisondi P, Girolomoni G: Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007; 6: 515-519.
11. Steinman L: Immune therapy for autoimmune diseases. Science 2004; 305: 212-216.
12. Xia YP, Li B, Hylton D, Detmar M, et al: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102: 161-168.
13. Detmar M, Brown LF, Schön MP, et al: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998; 111: 1-6.
14. Boehncke WH, Zollner TM, Dressel D, Kaufmann R: Induction of psoriasiform inflammation by a bacterial superantigen in the SCID-hu xenogeneic transplantation model. J Cutan Pathol 1997; 24: 1-7.
15. Baker BS, Brent L, Valdimarsson H, et al: Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines? Br J Dermatol 1992; 126: 105-110.
16. Creamer DM, Allen M, et al: Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002; 138: 791-796.
17. McColm JR, Geisen P, Hartnett ME: VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis 2004; 10: 512-520.
18. Bhisitkul RB: Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006; 90: 1542-1547.
19. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-1039.
20. Lee TH, Avraham H, Lee SH, Avraham S: Vascular endothelial growth factor modulates neutrophil transendothelial migration via upregulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem 2002; 277: 10445-10451.
21. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003; 9: 669-679.
22. Biedermann T, Zimmermann S, Himmelrich H, Gumy A, et al: IL-4 instructs Th1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2001; 2: 1054-1060.
23. Agnello D, Lankford CS, et al: Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 2003; 23: 147-161.
24. Li-Weber M, Krammer PH: Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nature 2003; 3: 534-543.
25. Oura H, Bertoncini J, Velasco P, Brown LF, Carmeliet P, Detmar M: A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 2003; 101: 560-567.